Usman Shah, MD
Critical Care Medicine · Newport Beach, CANPI 1952510851
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 87.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $3,286 and has fallen 95.5% since, to $147 in 2025. Among critical care medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $395.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$7K
- La Jolla Pharmaceutical Company$322
- Johnson & Johnson$186
- Medtronic$182
- Abiomed$147
- Boehringer Ingelheim$116
- plus $60 from 1 others
Across 5 payments — averaging $4021.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Octapharma USA, Inc.$20K
What the payments were for
- Consulting fees$4,50057%
- Speaking & faculty fees$2,40030%
- Food & beverage$99213%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 6 | $6,900 |
| La Jolla Pharmaceutical Company | 4 | $322 |
| Johnson & Johnson | 4 | $186 |
| Medtronic | 1 | $182 |
| Abiomed | 1 | $147 |
| Boehringer Ingelheim | 1 | $116 |
| CSL Behring | 3 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- The Swan-Ganz Catheter$1,600
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,400
- HemoSphere$1,350
- GIAPREZA$242
- KYPHON Balloon Kyphoplasty$182
- XARELTO$131
- OFEV$116
How this compares
$7,912 in reported general payments places this provider in the 90th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium-AlbuterolIpratropium/Albuterol Sulfate | 23 | $1,034 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $698 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Newport Beach
- Cedric Franklin RutlandRiverside$3.2M
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Ken YonedaSacramento$173K
- Praveen AkuthotaSan Diego$169K
- Ivan ChengSan Francisco$162K
- Brian ShermanOxnard$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.